Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 2

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (currently amended): A pyrrolidonecarboxamide of the formula

$$0 = \begin{bmatrix} 0 & R_2 \\ N & H \end{bmatrix}$$

I

in which

R<sup>1</sup> is phenyl which is optionally monosubstituted or disubstituted in the phenyl radical by alkyl, alkoxy, dialkylamino, halogen or trifluoromethyl, benzyl, phenylethyl or α-hydroxyphenylethyl; naphthyl or naphthylmethyl; thienyl, furyl, pyridyl, 1-alkylpyrrolidin-2-yl, pyrrolidino- or morpholino- alkyl; or cycloalkyl which can optionally possess a fused-on benzene ring;

R<sup>2</sup> is a radical of the formula

$$R_4$$
 or  $R_5$ 

Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 3

X is  $-CH_2$ , -CO, -O or  $-NR^3$ -;

R<sup>3</sup> is hydrogen or alkyl; and

R<sup>4</sup> is hydrogen or alkoxy;

R<sup>5</sup> is phenyl, heteroalkyl, aryloxy, alkoxy, alkanoyl or NR<sup>6</sup>R<sup>7</sup>;

R<sup>6</sup>— is hydrogen, alkyl, aralkyl, cycloalkylalkyl or alkoxycarbonylalkyl; and

R<sup>7</sup> is aryl, heteroaryl, alkyl, hydroxyalkyl or acyl;

pharmaceutically utilizable acid addition salts of basic compounds of the formula I, pharmaceutically utilizable salts of acid compounds of the formula I with bases, pharmaceutically utilizable esters of compounds of the formula I which contain hydroxyl or carboxyl groups, and hydrates or solvates thereof.

- 2. (currently amended): A compound as claimed in claim 1, in which R<sup>1</sup> is phenyl, 4-tolyl, 2,5-dimethylphenyl, 2-isopropylphenyl, 3-methoxyphenyl, 2-methyl-5-methoxyphenyl, benzyl, 2-phenylethyl, <del>2-(2-pyridyl)ethyl, 2-(2-thienyl)ethyl, or 2-indanyl-or 2-morpholinoethyl</del>.
- 3. (currently amended): A compound as claimed in claim 1, in which R<sup>1</sup> is cycloheptyl, 2-hydroxy-2-phenylethyl, 2-thienylmethyl, 2-furanylmethyl, 4-chlorobenzyl, 3-fluorophenyl, 2,4-dimethoxybenzyl or 2-chlorobenzyl.
- 4. (currently amended): A compound as claimed in claim 1, in which R<sup>1</sup> is 2-naphthyl, naphthalen-1-ylmethyl, 4-dimethylaminophenyl, 2-pyrrolidin-1-ylethyl, 1-methylpyrrolidin-2-ylethyl, 4-isopropylphenyl or 3,5-bistrifluoromethylphenyl.
- 5. (original): A compound as claimed in claim 1, in which R<sup>1</sup> is 2,5-dimethylphenyl, 2-isopropylphenyl or 2-methyl-5-methoxyphenyl.
- 6. (currently amended): A compound as claimed in claim 1, in which R<sup>2</sup> is biphenyl 4 yl, 4 methoxyphenyl, 4 phenoxyphenyl, 4 dimethylaminophenyl, 4 diethylaminophenyl, 4 phenylaminophenyl, 4 [N ethyl N (2 hydroxyethyl)amino]phenyl, 4 (N ethyl N

Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 4

isopropylamino)phenyl, 4 N (4,6-dimethyl-2-pyrimidinyl)aminophenyl, 4 [N-ethyl-N (4,6-dimethyl-2-pyrimidinyl)amino]phenyl, 4 [N-methyl-N (4,6-dimethyl-2-pyrimidinyl)amino]phenyl, 4-acetylphenyl, 9H-fluoren-2-yl, 9-oxo-9H-fluoren-2-yl or 9-ethylcarbazol-3-yl.

- 7. (withdrawn): A compound as claimed in claim 1, in which R<sup>2</sup> is 4-(N-ethoxycarbonylmethyl-N-phenylamino)phenyl, 4-(N-ethyl-N-phenylamino)phenyl, 4-(N-methyl-N-phenylamino)phenyl, 4-(N-cyclopropylmethyl-N-phenylamino)phenyl, 4-(N-isobutyl-N-phenylamino)phenyl, 4-(2-methoxybenzoylamino)phenyl, 4-(2,2-dimethylpropionylamino)phenyl, 4-(3-methylbutyrylamino)phenyl, 4-(cyclopropanecarbonylamino)phenyl, 4-(3-fluorobenzoylamino)phenyl or 4-[(furan-2-carbonyl)amino]phenyl.
- 8. (withdrawn): A compound as claimed in claim 1, in which R<sup>2</sup> is biphenyl-3-yl, 9H-fluoren-1-yl, 2-methoxydibenzofuran-3-yl, 4-(N-isopropyl-N-phenylamino)phenyl, 4-(N-benzyl-N-phenylamino)phenyl, 4-acetylaminophenyl, 4-benzoylaminophenyl, 4-phenylacetylaminophenyl, 4-[(benzo[1,3]dioxole-5-carbonyl)amino]phenyl or 4-(4-methoxybenzoylamino)phenyl.
- 9. (withdrawn): A compound as claimed in claim 1, in which R<sup>2</sup> is 9-ethyl-9H-carbazol-3-yl, 4-[N-ethyl-N-(4,6-dimethyl-2-pyrimidinyl)amino]phenyl, 4-[N-methyl-N-(4,6-dimethyl-2-pyrimidinyl)amino]phenyl, 4-(4,6-dimethyl-2-pyrimidinyl)amino]phenyl, 4-phenylamino-phenyl, 4-diethylaminophenyl, 4-(N-ethyl-N-isopropylamino)phenyl, 4-(N-ethyl-N-phenylamino)phenyl, 4-(N-ethyl-N-phenylamino)phenyl, 4-(N-ethyl-N-phenylamino)phenyl, 4-(N-ethyl-N-phenylamino)phenyl or 2,4-dimethoxybenzyl.
- 10. (currently amended): A compound as claimed in claim 1, selected from the group consisting of:
- rac. N-(9-Ethyl-9H-carbazol-3-yl)-5-oxo-1-(2-pyridin-2-ylethyl)pyrrolidine-3-carboxamide; rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(2-hydroxy-2-phenylethyl)-5-oxopyrrolidine-3-carboxamide;

Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 5

rac. N-(4-Diethylaminophenyl) 1 (2,5-dimethylphenyl) 5 oxopyrrolidine 3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-5-oxo-1-(2-thiophen-2-ylethyl)pyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(4-chlorobenzyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-5-oxo-1-thiophen-2-ylmethylpyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-furan-2-ylmethyl-5-oxopyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(2-isopropylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(5-methoxy-2-methylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N [4 (Ethylisopropylamino)phenyl] 1 (2,5 dimethylphenyl) 5 oxopyrrolidine-3 carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-5-oxo-1-phenethylpyrrolidine-3-carboxamide;

rac. Ethyl [(4-{[1-(2,5-dimethylphenyl)-5-oxopyrrolidine-3-

carbonyl]amino}phenyl)phenylamino]acetate;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-cycloheptyl-5-oxopyrrolidine-3-carboxamide;

rac. N-{4-[(4,6-Dimethylpyrimidin-2-yl)ethylamino]phenyl}-1-(5-methoxy-2-methylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-{4-[Ethyl-(2-hydroxyethyl)amino]phenyl}-1 (2,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-[4 (Ethylphenylamino)phenyl] 1-(2,5 dimethylphenyl) 5-oxopyrrolidine 3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(3-methoxyphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(2-chlorobenzyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-[4-(4,6-Dimethylpyrimidin 2-ylamino)phenyl]-1-(2,5-dimethylphenyl)-5-

oxopyrrolidine-3 carboxamide;

rac. N {4-[(4,6-Dimethylpyrimidin 2 yl)methylamino]phenyl}-1-(2,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-5-oxo-1-phenylpyrrolidine-3-carboxamide;

rac. N-{4-[(4,6-Dimethylpyrimidin-2-yl)methylamino]phenyl}-5-oxo-1-p-tolylpyrrolidine-3-carboxamide:

rac. N-[4 (Isopropylphenylamino)phenyl] 1 (2,5 dimethylphenyl) 5 oxopyrrolidine-3-carboxamide;

Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 6

rac. N [4 (Ethylphenylamino)phenyl] 1 (2 isopropylphenyl) 5 oxopyrrolidine 3-carboxamide;

rac. N-{4-[(4,6-Dimethylpyrimidin-2-yl)ethylamino]phenyl}-5-oxo-1-(2-pyridin-2-ylethyl)pyrrolidine-3-carboxamide;

rac. N [4 (4,6-Dimethylpyrimidin-2-ylamino)phenyl] 1 (2-isopropylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-[4-(4,6-Dimethylpyrimidin 2-ylamino)phenyl]-1-(5-methoxy-2-methylphenyl)-5-oxopyrrolidine 3-carboxamide;

rac. N-[4-(Methylphenylamino)phenyl]-1-(2,5 dimethylphenyl)-5 oxopyrrolidine-3-carboxamide;

rac. N [4 (Methylphenylamino)phenyl] 1 (2 isopropylphenyl) 5 oxopyrrolidine 3 carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(4-isopropylphenyl)-5-oxopyrrolidine-3-carboxamide; rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(3-fluorophenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N (4 Phenylaminophenyl) 1 (2,5-dimethylphenyl) 5 oxopyrrolidine 3 carboxamide; rac. N [4 (4,6-Dimethylpyrimidin 2 ylamino)phenyl] 1 indan 2 yl 5 oxopyrrolidine 3 carboxamide:

rac. N [4 (Ethylphenylamino)phenyl] 1 (5 methoxy 2 methylphenyl) 5 oxopyrrolidine 3 carboxamide;

rac. N-{4-[(4,6-Dimethylpyrimidin-2-yl)methylamino]phenyl}-1 (2-isopropylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-benzyl-5-oxopyrrolidine-3-carboxamide; rac. N-[4-(4,6-Dimethylpyrimidin-2-ylamino)phenyl] 5-oxo-1-p-tolylpyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-indan-2-yl-5-oxopyrrolidine-3-carboxamide;

rac. N-{4-[(4,6-Dimethylpyrimidin-2-yl)ethylamino]phenyl}-1-(2-hydroxy-2-phenylethyl)-5oxo-pyrrolidine-3-carboxamide;

rac. N (Biphenyl 4 yl) 1 (2,5-dimethylphenyl) 5 oxopyrrolidine 3 carboxamide; rac. N [4 (Cyclopropylmethylphenylamino)phenyl] 1 (5 methoxy 2 methylphenyl) 5 oxopyrrolidine 3 carboxamide;

Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 7

rac. N [4 (Isopropylphenylamino)phenyl]-1 (2 isopropylphenyl) 5 oxopyrrolidine 3 carboxamide;

rac. N (4 Phenylaminophenyl) 1-(2-isopropylphenyl) 5-oxopyrrolidine 3-carboxamide;

rac. N {4 [(4,6-Dimethylpyrimidin 2-yl)methylamino]phenyl}-1 (5 methoxy-2-methylphenyl)-5 oxopyrrolidine 3 carboxamide;

rac. N-{4-[(4,6-Dimethylpyrimidin-2-yl)ethylamino]phenyl}-1-(3-methoxyphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-{4-[(4,6-Dimethylpyrimidin-2-yl)methylamino]phenyl}-5 oxo-1-m tolylpyrrolidine-3-carboxamide;

rac. N-[4-(Cyclopropylmethylphenylamino)phenyl]-1-(2,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-{4-[(4,6-Dimethylpyrimidin-2-yl)ethylamino]phenyl}-1-(2-isopropylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. Ethyl [(4-{[1-(5-methoxy-2-methylphenyl) 5-oxopyrrolidine-3-carbonyl]amino}phenyl)phenylamino]acetate;

rac. N-[4-(Cyclopropylmethylphenylamino)phenyl]-1-(2-isopropylphenyl)-5-oxopyrrolidine-3-carboxamide:

rac. N [4 (Ethylphenylamino)phenyl] 1-indan 2-yl-5-oxopyrrolidine 3-carboxamide; and rac. N [4 (Isobutylphenylamino)phenyl] 1-(2-isopropylphenyl) 5-oxopyrrolidine 3-carboxamide.

or a pharmaceutically acceptable salt of such a compound.

11. (currently amended): A compound as claimed in claim 1, selected from the group consisting of:

rac. N [4-(2-Methoxybenzoylamino)phenyl] 1-(2,5-dimethylphenyl) 5-oxopyrrolidine-3-carboxamide:

rac. N-[4-(2,2-Dimethylpropionylamino)phenyl]-1-(2,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(2-morpholin-4-ylethyl)-5-oxopyrrolidine-3-carboxamide;

rac. N-(9-Ethyl-9H-carbazol-3-yl)-5-oxo-1-p-tolylpyrrolidine-3-carboxamide; and

Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 8

rac. N-(9-Ethyl-9H-carbazol-3-yl)-1-(2,4-dimethoxybenzyl)-5-oxopyrrolidine-3-carboxamide,

or a pharmaceutically acceptable salt of such a compound.

12. (withdrawn): A compound as claimed in claim 1, selected from the group consisting of: rac. N-[4-(4,6-Dimethylpyrimidin-2-ylamino)phenyl]-1-(4-dimethylaminophenyl)-5-oxopyrrolidine-3-carboxamide; and

rac. N-[4-(4,6-Dimethylpyrimidin-2-yl)methylaminophenyl]-1-(4-dimethylaminophenyl)-5-oxopyrrolidine-3-carboxamide.

13. (withdrawn): A compound as claimed in claim 1 for use as a therapeutic active compound.

14. (currently amended): A pharmaceutical composition comprising a galenic administration form which comprises a compound as claimed in claim 1 or a pharmaceutically acceptable salt of such a compound.

15. (withdrawn): The use of compounds as claimed in claim 1 for preventing or treating arthritis, diabetes and, especially, eating disturbances and obesity, or for producing corresponding pharmaceuticals.

16. (withdrawn): A process for preparing compounds as claimed in claim 1, characterized in that a pyrrolidinecarboxylic acid of the formula

Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 9

in which R<sup>1</sup> has the meaning given in claim 1, or a reactive derivative thereof, is reacted with an amine of the formula

$$\mathbf{H_2N}^{\mathbf{R_2}}$$
 IV

in which R<sup>2</sup> has the meaning given in claim 1, or a reactive derivative thereof, and, if desired, a stereoisomeric mixture which may possibly be obtained is resolved.

17. (withdrawn): A process for preparing compounds of the formula I defined in claim 1, in which R<sup>2</sup> is a radical of the formula (b), R<sup>5</sup> is -NR<sup>6</sup>R<sup>7</sup> and R<sup>7</sup> is acyl, characterized in that a corresponding compound, in which, however, R<sup>7</sup> is hydrogen, is acylated and, if desired, a stereoisomeric mixture which may possibly be obtained is resolved.

18. (withdrawn): A compound of the formula IV defined in claim 16, or a corresponding nitro precursor, selected from:

Ethyl [(4-nitrophenyl)phenylamino]acetate;

Ethyl [(4-aminophenyl)phenylamino]acetate;

Cyclopropylmethyl(4-nitrophenyl)phenylamine;

N-Cyclopropylmethyl-N-phenylphenylene-1,4-diamine;

Isobutyl(4-nitrophenyl)phenylamine;

N-Isobutyl-N-phenylphenylene-1,4-diamine;

Ethyl [(4-nitrophenyl)phenylamino]pentanoate;

Ethyl [(4-aminophenyl)phenylamino]pentanoate;

Benzyl(4-nitrophenyl)phenylamine; and

N-Benzyl-N-phenylphenylene-1,4-diamine.

19. (withdrawn): A compound of the formula III defined in claim 16, selected from:

rac. 1-Indan-2-yl-5-oxopyrrolidine-3-carboxylic acid;

rac. 1-Naphthalen-2-yl-5-oxopyrrolidine-3-carboxylic acid;

Response to Restriction Requirement dated August 15, 2005

Reply to Office Action of July 15, 2005

Docket No.: 1574-2 PCT/US

Page 10

rac. 1-(5-Methoxy-2-methylphenyl)-5-oxopyrrolidine-3-carboxylic acid;

rac. 5-Oxo-1-(2-pyridin-2-ylethyl)pyrrolidine-3-carboxylic acid;

rac. 1-Cycloheptyl-5-oxopyrrolidine-3-carboxylic acid;

rac. 1-(2-Hydroxy-2-phenylethyl)-5-oxopyrrolidine-3-carboxylic acid;

rac. 5-Oxo-1-(2-pyrrolidin-1-ylethyl)pyrrolidine-3-carboxylic acid;

rac. 1-[2-(1-Methylpyrrolidin-2-yl)ethyl]-5-oxopyrrolidine-3-carboxylic acid; and

rac. 1-(3-Fluorophenyl)-5-oxopyrrolidine-3-carboxylic acid.